AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22240172 — intervention group
Group type: EXPERIMENTAL
Intervention: Age above 24 years
Number of subjects: 227
Study 21069596 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MT) treatment with three cycles of 12 active sessions each, three times a week for one month, followed by one month of no treatment
Number of subjects: 60
Study 21069596 — intervention group
Group type: COMPARATOR
Intervention: Standard care (educational and entertainment activities)
Number of subjects: 60
Study 17706003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (starting dose 15 mg/day, adjusted 10-30 mg/day)
Number of subjects: 833
Study 17706003 — intervention group
Group type: COMPARATOR
Intervention: Safety Control (another antipsychotic)
Number of subjects: 833
Study 16115174 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 0
Study 16115174 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 0
Study 12391438 — intervention group
Group type: EXPERIMENTAL
Intervention: PL-irradiation
Number of subjects: 30
Study 12391438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no-irradiation)
Number of subjects: 30
Study 9563219 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60 mg twice daily for seven days)
Number of subjects: 10
Study 9563219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8129128 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 0.2 mg
Number of subjects: 20
Study 8129128 — intervention group
Group type: COMPARATOR
Intervention: Morphine 5 mg
Number of subjects: 20
Study 2799742 — intervention group
Group type: COMPARATOR
Intervention: Simple drainage
Number of subjects: 96
Study 2799742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline pleurodesis
Number of subjects: 96
Study 2799742 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc pleurodesis
Number of subjects: 96
Study 30305278 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand More AT (SMArT) Work intervention
Number of subjects: 146
Study 30305278 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 146
Study 28625382 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 318
Study 28625382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal Supplemental Oxygen (NSO)
Number of subjects: 318
Study 28625382 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyle Education (HLSE)
Number of subjects: 318
Study 26637222 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric care (CGC)
Number of subjects: 397
Study 26637222 — intervention group
Group type: COMPARATOR
Intervention: Orthopedic care (OC)
Number of subjects: 397
Study 23760221 — intervention group
Group type: EXPERIMENTAL
Intervention: Posthorax support vest®
Number of subjects: 2539
Study 23760221 — intervention group
Group type: COMPARATOR
Intervention: No vest (control group)
Number of subjects: 2539
Study 20592387 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg sodium selenite on days of radiotherapy and 300 microg sodium selenite on days without radiotherapy (Group A)
Number of subjects: 39
Study 20592387 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) received irradiation without any selenium substitution
Number of subjects: 39
Study 18054848 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid 2g/day
Number of subjects: 40
Study 18054848 — intervention group
Group type: COMPARATOR
Intervention: AHA regular diet
Number of subjects: 40
Study 15864241 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1205
Study 15864241 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1205
Study 15864241 — intervention group
Group type: COMPARATOR
Intervention: CKD (compared to normal renal function)
Number of subjects: 1205
Study 12930014 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide vaginal douching (20 ml of 3% hydrogen peroxide)
Number of subjects: 142
Study 12930014 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole (2 grams)
Number of subjects: 142
Study 10639383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (CRO) for 7 days (short course; n = 29)
Number of subjects: 57
Study 10639383 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (CRO) for 14 days (conventional; n = 28)
Number of subjects: 57
Study 8846276 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 G Quincke needle
Number of subjects: 60
Study 8846276 — intervention group
Group type: COMPARATOR
Intervention: 29 G Quincke needle
Number of subjects: 60
Study 1803175 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy
Number of subjects: 263
Study 1803175 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 263
Study 6840163 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-dinitrate (ISDN) 20 mg 4 times daily
Number of subjects: 12
Study 6840163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6840163 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-dinitrate (ISDN)
Number of subjects: 12
Study 30921171 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital storytelling and routine training
Number of subjects: 80
Study 30921171 — intervention group
Group type: COMPARATOR
Intervention: Routine training (Control)
Number of subjects: 80
Study 28427595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nitroglycerine (NTG) 200 μg
Number of subjects: 0
Study 26482786 — intervention group
Group type: EXPERIMENTAL
Intervention: Antismoking advertisements (various themes including anti-industry, health effects+anti-industry, sexual health, secondhand smoke, environment+anti-industry)
Number of subjects: 782
Study 26482786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antismoking advertisements)
Number of subjects: 782
Study 25221387 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 51
Study 25221387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 22902808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free DNA levels decrease in patients with severe TBI
Number of subjects: 65
Study 22902808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free DNA levels decrease in survivors from 0 to 24 hours
Number of subjects: 65
Study 22902808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off point for cf-DNA ratio
Number of subjects: 65
Study 19615062 — intervention group
Group type: EXPERIMENTAL
Intervention: BioGlue
Number of subjects: 10
Study 19615062 — intervention group
Group type: COMPARATOR
Intervention: Peri-strips
Number of subjects: 10
Study 16650261 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide (50% N2O/50% O2)
Number of subjects: 76
Study 16650261 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine infusion (20 mg over 15 minutes)
Number of subjects: 76
Study 14711185 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin plus tirofiban
Number of subjects: 68
Study 14711185 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin plus tirofiban
Number of subjects: 68
Study 10947750 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25 microg x kg(‐1) x min(‐1))
Number of subjects: 271
Study 10947750 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine
Number of subjects: 271
Study 10947750 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 271
Study 8828672 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous erythrocyte infusion (700-ml infusion, 42% hematocrit)
Number of subjects: 16
Study 8828672 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline only)
Number of subjects: 16
Study 8828672 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte infusion
Number of subjects: 16
Study 1385599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Depression Scale (HAM-D) items analyzed using Smallest Space Analysis (SSA-I)
Number of subjects: 0
Study 1385599 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet 'centrality'
Number of subjects: 0
Study 1385599 — intervention group
Group type: EXPERIMENTAL
Intervention: New combination and selection of items reflecting different facets of depression
Number of subjects: 0
Study 6317162 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperalimentation
Number of subjects: 80
Study 6317162 — intervention group
Group type: COMPARATOR
Intervention: No parenteral nutrition
Number of subjects: 80
Study 31074816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 intake ≥35 mg/d
Number of subjects: 75864
Study 31074816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 intake ≥30 μg/d
Number of subjects: 75864
Study 31074816 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high intake of both vitamins (B6 ≥35 mg/d and B12 ≥20 μg/d)
Number of subjects: 75864
Study 27203452 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage teaching technique (n=72)
Number of subjects: 142
Study 27203452 — intervention group
Group type: COMPARATOR
Intervention: Four-stage teaching technique (n=70)
Number of subjects: 142
Study 27487638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5 mg/kg
Number of subjects: 66
Study 27487638 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1 mg/kg
Number of subjects: 66
Study 24350872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive anti-hypertensive therapy with a systolic target of <140 mmHg within one hour
Number of subjects: 2839
Study 24350872 — intervention group
Group type: COMPARATOR
Intervention: Standard guideline recommended treatment of <180 mmHg
Number of subjects: 2839
Study 24350872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive anti-hypertensive therapy
Number of subjects: 2839
Study 24350872 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Intensive and Standard treatment)
Number of subjects: 2839
Study 22496198 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1b 250 μg
Number of subjects: 372
Study 22496198 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1b 50 μg
Number of subjects: 372
Study 22496198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 19346966 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (400 mg once daily) - immediate switch
Number of subjects: 246
Study 19346966 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir (400 mg once daily) - delayed switch
Number of subjects: 246
Study 17459076 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 39
Study 17459076 — intervention group
Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 39
Study 15927285 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab administration (27 patients)
Number of subjects: 55
Study 15927285 — intervention group
Group type: COMPARATOR
Intervention: Late abciximab administration (28 patients)
Number of subjects: 55
Study 14509516 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 0
Study 14509516 — intervention group
Group type: COMPARATOR
Intervention: Concurrent and adjuvant chemotherapy
Number of subjects: 0
Study 10824633 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.4 mg)
Number of subjects: 12
Study 10824633 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.5 mg)
Number of subjects: 12
Study 10824633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiologic saline solution)
Number of subjects: 12
Study 8865766 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepractice
Number of subjects: 0
Study 8865766 — intervention group
Group type: COMPARATOR
Intervention: No prepractice (Control)
Number of subjects: 0
Study 1615141 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide, 0.43 mg/70 kg, administered by subcutaneous injection
Number of subjects: 20
Study 1615141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6425892 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 1.2 mg
Number of subjects: 0
Study 6425892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6425892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 0.5 mg, 1.0 mg, and 1.5 mg
Number of subjects: 0
Study 6425892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in the second experiment)
Number of subjects: 0
Study 30312183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midodrine for 30 days
Number of subjects: 75
Study 30312183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midodrine for 2 days
Number of subjects: 75
Study 30312183 — intervention group
Group type: COMPARATOR
Intervention: Albumin infusion
Number of subjects: 75
Study 30234623 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (BTX‐A) injection into the gastrocnemius‐soleus muscle at the time of hindfoot stall
Number of subjects: 62
Study 30234623 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection into the gastrocnemius‐soleus muscle at the time of hindfoot stall
Number of subjects: 62
Study 30234623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue BTX‐A injection at 12 weeks after the first injection (T2)
Number of subjects: 62
Study 30234623 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall manipulation and cast protocol (with or without BTX‐A)
Number of subjects: 62
Study 27107601 — intervention group
Group type: EXPERIMENTAL
Intervention: Telfa nasal packs in sutures + telfa group (n=22)
Number of subjects: 66
Study 27107601 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocell nasal packs in merocel alone group (n=22)
Number of subjects: 66
Study 27107601 — intervention group
Group type: COMPARATOR
Intervention: No packs in sutures alone group (n=22)
Number of subjects: 66
Study 23800984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg/kg)
Number of subjects: 150
Study 23800984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (5 mg/kg)
Number of subjects: 150
Study 23800984 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 150
Study 23800984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine and ketamine
Number of subjects: 150
Study 21858591 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey
Number of subjects: 6000
Study 21858591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail survey
Number of subjects: 6000
Study 21858591 — intervention group
Group type: COMPARATOR
Intervention: Postal mail survey
Number of subjects: 6000
Study 20229022 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise (CONT)
Number of subjects: 14
Study 20229022 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise (INT)
Number of subjects: 14
Study 20229022 — intervention group
Group type: COMPARATOR
Intervention: Acute cold exposure (ACE)
Number of subjects: 14
Study 20229022 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise recovery (REC)
Number of subjects: 14
Study 18833106 — intervention group
Group type: EXPERIMENTAL
Intervention: Torin (generic sertraline)
Number of subjects: 40
Study 18833106 — intervention group
Group type: COMPARATOR
Intervention: Zoloft (original sertraline)
Number of subjects: 40
Study 16225510 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 2
Study 16225510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 11980557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-containing antiretroviral therapy
Number of subjects: 197
Study 10073742 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin
Number of subjects: 10
Study 10073742 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg terazosin
Number of subjects: 10
Study 10073742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7718461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy at 1-week intervals
Number of subjects: 225
Study 7718461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy at 2-week intervals
Number of subjects: 225
Study 7718461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy at 3-week intervals
Number of subjects: 225
Study 1904163 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms morning and evening
Number of subjects: 12
Study 1904163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7027431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine (Bisolvon) 48 mg daily for 3 weeks
Number of subjects: 32
Study 7027431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29668401 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 20
Study 29668401 — intervention group
Group type: COMPARATOR
Intervention: Complementary and Alternative Medicine (CAM)
Number of subjects: 20
Study 28719012 — intervention group
Group type: EXPERIMENTAL
Intervention: ART plus 5 days of IVIG
Number of subjects: 10
Study 28719012 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 10
Study 25482574 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenia patients
Number of subjects: 32
Study 25482574 — intervention group
Group type: COMPARATOR
Intervention: Schizotypal personality disorder (SPD) patients
Number of subjects: 32
Study 25482574 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy controls (HCs)
Number of subjects: 32
Study 23582638 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant adenovirus HIV1 vaccine
Number of subjects: 777
Study 21378591 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft toric contact lenses (2 toric lenses in phase 1, 4 toric lenses in phase 2)
Number of subjects: 45
Study 21378591 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft toric contact lenses (4 toric lenses in phase 2)
Number of subjects: 45
Study 19142413 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (mean dose 9.6 mg/day)
Number of subjects: 32
Study 16644602 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone plus cholestyramine
Number of subjects: 25
Study 16644602 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cholestyramine
Number of subjects: 25
Study 12970729 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 1% lignocaine in the periprostatic tissue prior to biopsy
Number of subjects: 64
Study 12970729 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy
Number of subjects: 64
Study 11194411 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 34
Study 11194411 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 34
Study 8672415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10 or 20 micrograms/d for 4, 5 and 9 weeks
Number of subjects: 3
Study 8672415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol administration
Number of subjects: 3
Study 1596003 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained-release theophylline (Theodur)
Number of subjects: 18
Study 1596003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6140978 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine
Number of subjects: 0
Study 6140978 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 6140978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31391387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 254
Study 31391387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 29540227 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating and physical activity promotion intervention (HE + PA intervention)
Number of subjects: 435
Study 29540227 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating promotion intervention (HE intervention)
Number of subjects: 435
Study 29540227 — intervention group
Group type: COMPARATOR
Intervention: Physical activity promotion intervention (PA intervention)
Number of subjects: 435
Study 29540227 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 435
Study 27184759 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000µg/month oral vitamin D3 by the mother (group A)
Number of subjects: 230
Study 27184759 — intervention group
Group type: EXPERIMENTAL
Intervention: 10µg/d by the infant (group B)
Number of subjects: 230
Study 27184759 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (group C)
Number of subjects: 230
Study 24149079 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(B)-adjuvanted vaccine
Number of subjects: 274
Study 24149079 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine
Number of subjects: 274
Study 23788090 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body mass patients with moderate knowledge about the disease
Number of subjects: 1986
Study 23788090 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body mass patients with full knowledge of health indicators
Number of subjects: 1986
Study 23788090 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body mass patients with supportive family environment
Number of subjects: 1986
Study 23788090 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body mass patients with favourable socio-living situation
Number of subjects: 1986
Study 23788090 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body mass patients requiring less professional care
Number of subjects: 1986
Study 23788090 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body mass patients with normal blood pressure
Number of subjects: 1986
Study 23788090 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body mass patients with normal triglyceride concentrations
Number of subjects: 1986
Study 23788090 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body mass patients with normal total cholesterol concentrations
Number of subjects: 1986
Study 23788090 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with obesity and no physical activity
Number of subjects: 1986